Ruben Mesa/LinkedIn
Jun 14, 2026, 08:46
Ruben Mesa: Exploring New Treatment Options for Myelofibrosis-Related Anemia at EHA 2026
Ruben Mesa, President of Cancer National Service Line at Advocate Health, shared a post on LinkedIn:
“EHA 2026 glad to have been a coinvestigator on Independence showing anemia benefit with Luspatercept in MF Anemia with positive trend for the intervention, with potential confounders from differences in international transfusion practices.”
Stay updated with Hemostasis Today.
-
Jun 14, 2026, 08:32Manuela Spadea: Celebrating Recognition for Pediatric HSCT Research at EHA 2026
-
Jun 14, 2026, 08:17Amber Yates: Honoring the Sickle Cell Community Behind the Rise Up Study
-
Jun 14, 2026, 06:19Sharmila Manian: World Blood Donor Day – Where Generosity Meets Smart Medicine
-
Jun 14, 2026, 06:04Vishnu R.: FedServ Employees Unite to Save Lives Through Blood Donation
-
Jun 13, 2026, 20:28Tarun Tyagi: Translational Insights into Severe Immune Thrombocytopenia
-
Jun 13, 2026, 18:25Miguel Gómez Álvarez: Reviewing Inflammation, Transplantation, and Gene Therapy in Hemoglobinopathies
-
Jun 13, 2026, 18:24Ana Pedrero Gil: Why Factor XIII Deficiency Is Often Overlooked During Acute Bleeding
-
Jun 13, 2026, 18:23Tobias Degsell: Building Stronger Bridges Across Disciplines, Countries, and Perspectives at EHA 2026
-
Jun 13, 2026, 18:22Haemoglobinopathies, Innovation, Patient Experience, and Equitable Access at EHA 2026 – TIF